These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 10195791)

  • 1. Immunogenicity of synthetic HIV-1 V3 loop peptides by MPL adjuvanted pH-sensitive liposomes.
    Chang JS; Choi MJ; Kim TY; Cho SY; Cheong HS
    Vaccine; 1999 Mar; 17(11-12):1540-8. PubMed ID: 10195791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Studies on in vivo induction of HIV-1 envelope-specific cytotoxic T lymphocytes by synthetic peptides from the V3 loop region of HIV-1 IIIB gp 120.
    Nehete PN; Casement KS; Arlinghaus RB; Sastry KJ
    Cell Immunol; 1995 Feb; 160(2):217-23. PubMed ID: 7720083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brucella abortus conjugated with a peptide derived from the V3 loop of human immunodeficiency virus (HIV) type 1 induces HIV-specific cytotoxic T-cell responses in normal and in CD4+ cell-depleted BALB/c mice.
    Lapham C; Golding B; Inman J; Blackburn R; Manischewitz J; Highet P; Golding H
    J Virol; 1996 May; 70(5):3084-92. PubMed ID: 8627787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased immunogenicity of HIV envelope subunit complexed with alpha2-macroglobulin when combined with monophosphoryl lipid A and GM-CSF.
    Liao HX; Cianciolo GJ; Staats HF; Scearce RM; Lapple DM; Stauffer SH; Thomasch JR; Pizzo SV; Montefiori DC; Hagen M; Eldridge J; Haynes BF
    Vaccine; 2002 May; 20(17-18):2396-403. PubMed ID: 12009296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved humoral and cellular immune responses against the gp120 V3 loop of HIV-1 following genetic immunization with a chimeric DNA vaccine encoding the V3 inserted into the hepatitis B surface antigen.
    Fomsgaard A; Nielsen HV; Bryder K; Nielsen C; Machuca R; Bruun L; Hansen J; Buus S
    Scand J Immunol; 1998 Apr; 47(4):289-95. PubMed ID: 9600309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity of synthetic HIV-1 gp120 V3-loop peptide-conjugate immunogens.
    Conley AJ; Conard P; Bondy S; Dolan CA; Hannah J; Leanza WJ; Marburg S; Rivetna M; Rusiecki VK; Sugg EE
    Vaccine; 1994 Apr; 12(5):445-51. PubMed ID: 8023553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brucella abortus conjugated with a gp120 or V3 loop peptide derived from human immunodeficiency virus (HIV) type 1 induces neutralizing anti-HIV antibodies, and the V3-B. abortus conjugate is effective even after CD4+ T-cell depletion.
    Golding B; Inman J; Highet P; Blackburn R; Manischewitz J; Blyveis N; Angus RD; Golding H
    J Virol; 1995 Jun; 69(6):3299-307. PubMed ID: 7745677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of cross-reactive cytotoxic T-lymphocyte responses specific for HIV-1 gp120 using saponin adjuvant (QS-21) supplemented subunit vaccine formulations.
    Newman MJ; Wu JY; Gardner BH; Anderson CA; Kensil CR; Recchia J; Coughlin RT; Powell MF
    Vaccine; 1997 Jun; 15(9):1001-7. PubMed ID: 9261947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of helper T cell-inducing peptides from conserved regions in HIV-1 env in a noncovalent mixture with a CTL-inducing V3-loop peptide for in vivo induction of long-lasting systemic CTL response.
    Nehete PN; Arlinghaus RB; Sastry KJ
    Viral Immunol; 1994; 7(4):189-97. PubMed ID: 7576033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced CD8+ T cell immune response against a V3 loop multi-epitope polypeptide (TAB13) of HIV-1 Env after priming with purified fusion protein and booster with modified vaccinia virus Ankara (MVA-TAB) recombinant: a comparison of humoral and cellular immune responses with the vaccinia virus Western Reserve (WR) vector.
    Gómez CE; Rodríguez D; Rodríguez JR; Abaitua F; Duarte C; Esteban M
    Vaccine; 2001 Dec; 20(5-6):961-71. PubMed ID: 11738764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
    Kang CY; Luo L; Wainberg MA; Li Y
    Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hemagglutinating virus of Japan protein is efficient for induction of CD4+ T-cell response by a hepatitis B core particle-based HIV vaccine.
    Takeda S; Shiosaki K; Kaneda Y; Nakasatomi T; Yoshizaki H; Someya K; Konno Y; Eda Y; Kino Y; Yamamoto N; Honda M
    Clin Immunol; 2004 Jul; 112(1):92-105. PubMed ID: 15207786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. P5 HER2/neu-derived peptide conjugated to liposomes containing MPL adjuvant as an effective prophylactic vaccine formulation for breast cancer.
    Shariat S; Badiee A; Jalali SA; Mansourian M; Yazdani M; Mortazavi SA; Jaafari MR
    Cancer Lett; 2014 Dec; 355(1):54-60. PubMed ID: 25224570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficient CD8+ T cell response to the HIV-env V3 loop epitope from multiple virus isolates by a DNA prime/vaccinia virus boost (rWR and rMVA strains) immunization regime and enhancement by the cytokine IFN-gamma.
    Gómez CE; Abaitua F; Rodríguez D; Esteban M
    Virus Res; 2004 Sep; 105(1):11-22. PubMed ID: 15325077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single peptide and anti-idiotype based immunizations can broaden the antibody response against the variable V3 domain of HIV-1 in mice.
    Boudet F; Keller H; Kieny MP; Thèze J
    Mol Immunol; 1995 May; 32(7):449-57. PubMed ID: 7783749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein.
    Peet NM; McKeating JA; de Souza JB; Roitt IM; Delves PJ; Lund T
    Virology; 1998 Nov; 251(1):59-70. PubMed ID: 9813203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modification of delivery system enhances MHC nonrestricted immunogenicity of V3 loop region of HIV-1 gp120.
    Ahluwalia A; Gokulan K; Nath I; Rao DN
    Microbiol Immunol; 1997; 41(10):779-84. PubMed ID: 9403501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancement of HIV type 1 vaccine immunogenicity by block copolymer adjuvants. I. Induction of high-titer, long-lasting, cross-reactive antibodies of broad isotype.
    McNicholl JM; Bond KB; Ruhadze ER; Olsen MR; Takayama K; Hunter RL
    AIDS Res Hum Retroviruses; 1998 Nov; 14(16):1457-71. PubMed ID: 9824324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monophosphoryl lipid A enhances both humoral and cell-mediated immune responses to DNA vaccination against human immunodeficiency virus type 1.
    Sasaki S; Tsuji T; Hamajima K; Fukushima J; Ishii N; Kaneko T; Xin KQ; Mohri H; Aoki I; Okubo T; Nishioka K; Okuda K
    Infect Immun; 1997 Sep; 65(9):3520-8. PubMed ID: 9284115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design of a complete synthetic peptide-based AIDS vaccine with a built-in adjuvant.
    Nardelli B; Defoort JP; Huang W; Tam JP
    AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1405-7. PubMed ID: 1466968
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.